Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCO DVT Study of edoxaban duration in cancer-associated isolated distal deep vein thrombosis
jRCTs051190010Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of edoxaban in deep vein thrombosis (DVT) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Symptomatic venous thromboembolism recurrence or venous thromboembolism-related death at 12 months. Started May 2019; status: completed.
02
Drugs
edoxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on jRCTs051190010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190010.